These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1812438)

  • 1. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
    Fredriksen JH; Rosenqvist E; Wedege E; Bryn K; Bjune G; Frøholm LO; Lindbak AK; Møgster B; Namork E; Rye U
    NIPH Ann; 1991 Dec; 14(2):67-79; discussion 79-80. PubMed ID: 1812438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
    Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
    NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Closs O; Frøholm LO; Grønnesby JK; Høiby EA; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):81-91; discussion 91-3. PubMed ID: 1812439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a second generation group B meningococcal vaccine.
    Frasch CE; Sacchi CT; Brandiolone MC; Vieiera VS; Leite LC
    NIPH Ann; 1991 Dec; 14(2):225-30; discussion 230-1. PubMed ID: 1812436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.
    Høiby EA; Rosenqvist E; Frøholm LO; Bjune G; Feiring B; Nøkleby H; Rønnild E
    NIPH Ann; 1991 Dec; 14(2):147-55; discussion 155-6. PubMed ID: 1812429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis.
    Høiby EA; Bjune G; Frøholm LO; Eng J; Halstensen A; Rosenqvist E; Rønnild E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):107-21; discussion 121-3. PubMed ID: 1812424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt.
    Norheim G; Tunheim G; Næss LM; Kristiansen PA; Caugant DA; Rosenqvist E
    Scand J Immunol; 2012 Aug; 76(2):99-107. PubMed ID: 22537024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.
    Aavitsland P; Bjune G; Aasen S; Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):133-4; discussion 136-7. PubMed ID: 1812426
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis.
    Frøholm LO; Caugant DA; Holten E; Høiby EA; Rosenqvist E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):139-43; discussion 144-6. PubMed ID: 1812428
    [No Abstract]   [Full Text] [Related]  

  • 14. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials.
    Nøkleby H; Feiring B
    NIPH Ann; 1991 Dec; 14(2):95-101; discussion 101-2. PubMed ID: 1812440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The meningococcal serogroup B vaccine protection trial in Norway 1988-1991: trial surveillance by an independent group.
    Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):135-6; discussion 136-7. PubMed ID: 1812427
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnostic work with suspected cases of systemic meningococcal disease in the Norwegian serogroup B vaccine protection trials.
    Holten E; Bruun JN; Hellum KB; Maeland JA
    NIPH Ann; 1991 Dec; 14(2):103-6; discussion 121-3. PubMed ID: 1812423
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum opsonins to serogroup B meningococci after disease and vaccination.
    Halstensen A; Lehmann AK; Guttormsen HK; Vollset SE; Bjune G; Naess A
    NIPH Ann; 1991 Dec; 14(2):157-65; discussion 166-7. PubMed ID: 1812430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.